Polymorphisms in the multidrug-resistance 1 gene related to glucocorticoid response in rheumatoid arthritis treatment

[1]  Yoshiya Tanaka,et al.  Disease control by regulation of P-glycoprotein on lymphocytes in patients with rheumatoid arthritis. , 2015, World journal of experimental medicine.

[2]  Xiang Gao,et al.  Contribution of MDR1 gene polymorphisms on IBD predisposition and response to glucocorticoids in IBD in a Chinese population , 2015, Journal of digestive diseases.

[3]  Huiyuan Li,et al.  Association of ABCB1 gene polymorphisms and haplotypes with therapeutic efficacy of glucocorticoids in Chinese patients with immune thrombocytopenia. , 2014, Human immunology.

[4]  A. Gerards,et al.  Response to glucocorticoids at 2 weeks predicts the effectiveness of DMARD induction therapy at 3 months: post hoc analyses from the tREACH study , 2012, Annals of the rheumatic diseases.

[5]  D. van Zeben,et al.  Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial , 2012, Annals of the rheumatic diseases.

[6]  K. Saito,et al.  Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[7]  M. Boers,et al.  Effects of glucocorticoids on radiological progression in rheumatoid arthritis. , 2007, The Cochrane database of systematic reviews.

[8]  R. Ho,et al.  MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. , 2006, Journal of pharmaceutical sciences.

[9]  M. Droździk,et al.  The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs , 2006, European Journal of Clinical Pharmacology.

[10]  A. Pawlik,et al.  The MDR1 3435 polymorphism in patients with rheumatoid arthritis. , 2004, International journal of clinical pharmacology and therapeutics.

[11]  Peter W. Swaan,et al.  Structural Determinants of P-Glycoprotein-Mediated Transport of Glucocorticoids , 2003, Pharmaceutical Research.

[12]  I. Roots,et al.  MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes , 2003, Fundamental & clinical pharmacology.

[13]  J. Carlstedt-Duke,et al.  Involvement of multidrug resistance proteins (MDR) in the modulation of glucocorticoid response , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  M. Fromm,et al.  The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. , 2001, Pharmacogenetics.

[15]  J. Jacobs,et al.  Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis , 2001, Annals of the rheumatic diseases.

[16]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. van Riel,et al.  Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. , 1998, Arthritis and rheumatism.

[18]  R Hori,et al.  Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. , 1992, The Journal of biological chemistry.

[19]  B. McConkey,et al.  High-dose intravenous methylprednisolone in rheumatoid arthritis. , 1982, Annals of the rheumatic diseases.